Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1997 Jan-Mar;7(1):40-8.
doi: 10.1177/112067219700700108.

Low-dosage mitomycin C as an adjunct to trabeculectomy. A prospective controlled study

E Martini  1 , G L Laffi, C Sprovieri, L Scorolli
Affiliations
Clinical Trial

Low-dosage mitomycin C as an adjunct to trabeculectomy. A prospective controlled study

E Martini et al. Eur J Ophthalmol. 1997 Jan-Mar.

Abstract

Purpose: To assess the advantages and adverse effects of intraoperative low-dose Mitomycin C in filtering glaucoma surgery.

Methods: Sixty eyes of 48 patients undergoing surgery for uncontrolled glaucoma were randomized to two groups: one underwent standard trabeculectomy, the other had trabeculectomy with intraoperative application of 0.1 mg/ml mitomycin C. Follow-up was at least one year.

Results: The success rate (IOP < 18 mmHg) was 96.6% in the mitomycin C group and 73.3% in the control group. Mean IOP at one year of successful cases was 11.1 +/- 3.1 mmHg in the mitomycin C group and 16.4 +/- 6.1 mmHg in controls (p < 0.0001). Two patients in the mitomycin C group (6.6%) and six (20%) in the control group needed antiglaucomatous drugs to keep IOP below 18 mmHg.

Conclusions: Mitomycin C is a useful adjunct to glaucoma surgery. Adverse effects at the dosage used are mainly due to hypotony and are preventable with two-layer suture. Low-dose mitomycin C may be useful in standard primary trabeculectomy.

PubMed Disclaimer

MeSH terms

LinkOut - more resources